Jeroen van de Pol

105 4 Cost-utility and cost-effectiveness analysis of a clinical medication review [16] Kempen TGH, van de Steeg-van Gompel CH, Hoogland P et al. Large scale implementation of clinical medication reviews in Dutch community pharmacies: drug-related problems and interventions. Int J Clin Pharm 2014;36:630-5. [17] Vinks TH, Egberts TC, de Lange TM et al. Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial. Drugs Aging 2009;26:123-33. [18] Santschi V, Chiolero A, Paradis G et al. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review andmeta-analysis of randomized controlled trials. Diabetes Care 2012;35:2706-17. [19] Jodar-Sanchez F, Malet-Larrea A, Martin JJ et al. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics 2015;33:599-610. [20] Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health 2015;18:161-72. [21] Bulajeva A, Labberton L, Leikola S et al. Medication review practices in European countries. Res Social Adm Pharm 2014;10:731-40. [22] Ramsey S, Willke R, Briggs A et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005;8:521-33. [23] Verdoorn S, Kwint HF, Blom J et al. DREAMeR: Drug use Reconsidered in the Elderly using goal Attainment scales during Medication Review; study protocol of a randomised controlled trial. BMC Geriatr 2018;18:190. [24] Hoeymans N, van Lindert H, Westert GP. The health status of the Dutch population as assessed by the EQ-6D. Qual Life Res 2005;14:655-663. [25] Versteegh MM, Vermeulen KM, Evers SMAA, et al. Dutch Tariff for the Five-Level Version of EQ- 5D. Value Health 2016;19:343-352. [26] Van Blijswijk SC, ChanOY, van Houwelingen AH et al. Self-Reported Hindering Health Complaints of Community-Dwelling Older Persons: A Cross-Sectional Study. PLoS One 2015;10:e0142416. [27] Oldenmenger WH, de Raaf PJ, de Klerk C et al. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review. J Pain Symptom Manage 2013;45:1083-1093. [28] Bouwmans C, Hakkaart-van Roijen, L Koopmanschap et al. Handleiding iMTA Medical Cost Questionnaire [iMCQ]. Rotterdam: iMTA, Erasmus Universiteit Rotterdam, 2013 [www.imta.nl] . [29] Hakkaart-van Roijen L, van der Linden N, Bouwmans C et al. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Institute for Medical Technology Assessment; Erasmus Universiteit Rotterdam; 2015. [30] CBS Statline. Jaarmutatie consumentenprijsindex vanaf 1963. URL: https://opendata.cbs.nl/ statline/#/CBS/nl/dataset/70936ned/table?ts=1535353425460 [31] Koster L, Hoeben T, Peeters C et al. Generieke kosten medicatiebeoordeling - Een instrument om te komen tot afspraken. 27 januari 2014.